Markus Zabransky

Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope ^® in children requiring growth hormone treatment

Roland Pfäffle, Karl Otfried Schwab, Otilia Mărginean et al. · Therapeutic Advances in Endocrinology and Metabolism · 2013 · 33 citations · Full text

Pharmacy, Endocrinology, Pediatrics +17

Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow‐on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis

R Stanhope, Fritz Sörgel, Patricia Gravel et al. · The Journal of Clinical Pharmacology · 2010 · 23 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data

T E Romer, Markus Zabransky, Mieczysław Walczak et al. · Biologics in Therapy · 2011 · 20 citations · Full text

Medicine, Endocrinology, Pediatrics +17

Harmonizing national growth references for multi‐centre surveys, drug monitoring and international postmarketing surveillance

Michael Hermanussen, Christian Aßmann, H Wöhling et al. · Acta Paediatrica · 2011 · 16 citations · Full text

Natural Resources, Health Sciences, Health Services Research +14

Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study

Markus Zabransky, Robert Rapaport, P Saenger et al. · Medical Devices Evidence and Research · 2013 · 13 citations · Full text

Pharmacy, Endocrinology, Drug Delivery +14